Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Track: The Visual Abstract
Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.
Track: El Resumen Visual
¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada?
El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en diálisis con alto riesgo cardiovascular.
Revisa nuestro más reciente resumen visual y acompáñanos en la próxima discusión de #NephJC.
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates
Dialysis deferred, logic recycled: BICAR ICU2
NephJC Shorts: zilebesiran silencing hypertension via RNA interference
NephJC Shorts: Salt reduction still lowers BP
NephJC Shorts: BedMed and Chronotherapy
BaSICS brings balance to the fluid wars
The LANDMARK Visual Abstract
Continuing on the cycling theme for the summer, Missy Hanna has created a delightful visual abstract!
A LANDMARK Trial in Mineral Bone Disease?
Gadolinium in CKD 4 , 5 and dialysis systematic review and meta analysis. The Visual Abstract
Vicki Sandys put together the visual abstract for this week’s NephJC
